Menu

FDA Goes After Two Stem Cell Clinics

The agency raided one that was using a stem cell-smallpox vaccine combo, and sent a warning to another to obey best practices.

Aug 29, 2017
Kerry Grens

WIKIMEDIA, BESTINPLASTICSLast Friday (August 25), agents from the US Food and Drug Administration (FDA) seized five vials of live smallpox vaccine from a medical outfit in California that was using it in combination with fat-derived stem cells to treat patients with cancer. “The unproven and potentially dangerous treatment was being injected intravenously and directly into patients’ tumors,” according to a statement from the FDA.

The day before, the agency sent a letter to Florida-based US Stem Cell Clinic, detailing its deviations from the law. Among them: not having a license for its autologous stem cell treatments, which are given to patients with Parkinson’s disease, Crohn’s, congestive heart failure, and other conditions. The FDA also says the business didn’t ensure sterility of its products, follow proper procedures for cleaning equipment, or require staff to wear clean clothing. US Stem Cell Clinic has 15 days to outline how it will correct the problems FDA detailed.

See “Women Lose Vision After Stem Cell Treatment

“Stem cell clinics that mislead vulnerable patients into believing they are being given safe, effective treatments that are in full compliance with the law are dangerously exploiting consumers and putting their health at risk,” FDA Commissioner Scott Gottlieb says in a press release.

According to The New York Times, California-based StemImmune says it obtained the smallpox vaccine legally. But the Centers for Disease Control and Prevention, which supplied some of it, alleges that the company didn’t disclose its intention of treating patients, instead asking for the vials to immunize staff members doing cancer research.

There are numerous stem cell clinics in operation in the U.S., which Gottlieb says will be “vigorously” investigated. The Washington Post repots that the FDA will develop clear guidelines for how they might achieve the agency’s blessing.

“I’m encouraged by today’s news but it is premature to claim that the FDA has cracked down on such businesses or will definitely do so over the next several months,” University of Minnesota bioethicist Leigh Turner tells HealthNewsReview.org. “It is relatively easy to make bold pronouncements. We’ll see whether the FDA is prepared to engage in the difficult work needed to better regulate this marketplace.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.